<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336593</url>
  </required_header>
  <id_info>
    <org_study_id>QIV 0217</org_study_id>
    <nct_id>NCT03336593</nct_id>
  </id_info>
  <brief_title>Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population</brief_title>
  <official_title>A Bridging Study to Assess Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in
      Indonesian Population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the protectivity rate of Quadrivalent Influenza HA vaccine 28 days after
      immunization in Indonesian population.

      To describe immunogenicity of quadrivalent Influenza HA vaccine in all subjects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects 9- 40 years of age: Experimental, randomized, double blind bridging study Subjects 6 months - 8 years of age: Experimental, open labeled bridging study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The study for subjects 9-40 years of age is randomized, double blind study. While the study for subjects 6 months-8 years of age is open labeled study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with an anti-influenza titer &gt;= 1:40 HI units</measure>
    <time_frame>28 days after the last dose immunization</time_frame>
    <description>The anti-influenza antibody serological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>GMT in all subjects; comparison of GMT between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison of GMT between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with increasing antibody titer &gt;= 4 times</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with increasing antibody titer &gt;= 4 times: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with transition of seronegative to seropositive</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with transition of seronegative to seropositive: in all subjects; comparison between one dose of quadrivalent and trivalent influenza HA vaccine in subjects 9-40 years old; and comparison between each batch number of quadrivalent influenza HA vaccine in subjects 9-40 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with at least one immediate reaction</measure>
    <time_frame>30 minutes after each vaccination</time_frame>
    <description>Immediate reaction (local reaction or systemic event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with at least one of these adverse events</measure>
    <time_frame>within 72 hours, between 72 hours to 28 days after vaccination</time_frame>
    <description>At least one of these adverse events, expected or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Serious adverse event occurring from inclusion until 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison adverse events between quadrivalent and trivalent influenza HA vaccine.</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events occuring until 28 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events between each batch number of quadrivalent influenza HA vaccine.</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events occuring until 28 days after vaccination</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">810</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>QIV batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV batch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV batch 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml of trivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV (subjects 6-35 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 dose of 0.25 ml of quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV (subjects 3-8 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 dose of 0.5 ml of quadrivalent influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Vaccine</intervention_name>
    <description>1 or 2 doses of Quadrivalent Influenza Vaccine depends on age</description>
    <arm_group_label>QIV batch 1</arm_group_label>
    <arm_group_label>QIV batch 2</arm_group_label>
    <arm_group_label>QIV batch 3</arm_group_label>
    <arm_group_label>QIV (subjects 6-35 months)</arm_group_label>
    <arm_group_label>QIV (subjects 3-8 years)</arm_group_label>
    <other_name>QIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Influenza Vaccine</intervention_name>
    <description>1 dose of Trivalent Influenza Vaccine</description>
    <arm_group_label>Trivalent Influenza Vaccine</arm_group_label>
    <other_name>TIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Subjects 9 - 40 Years of Age:

          -  Healthy

          -  Properly informed about the study and having signed the informed consent form

          -  Subject/Parent will commit themselves to comply with the instructions of the
             investigator and the schedule of the trial.

        Inclusion Criteria for Subjects 6 Months - 8 Years of Age:

          -  Healthy

          -  Parents have been informed properly regarding the study and signed the informed
             consent form

          -  Parents will commit themselves to comply with the instructions of the investigator and
             the schedule of the trial

        Exclusion Criteria:

          -  Subject concomitantly enrolled or scheduled to be enrolled in another trial

          -  Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature &gt;= 37.5 C )

          -  Known history of allergy to egg and or chicken protein or any component of the
             vaccines

          -  History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection

          -  Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products or long term
             corticotherapy (&gt; 2 weeks).

          -  Pregnancy &amp; Lactation (Adult)

          -  Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives

          -  Subject already immunized with influenza vaccine within 1 year.

          -  Subjects receive any vaccination within 1 month before and after immunization of
             Quadrivalent Influenza Vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meita Dhamayanti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasan Sadikin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia Sjafri Bachtiar</last_name>
    <phone>62222033755</phone>
    <phone_ext>14101</phone_ext>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Garuda Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meita Dhamayanti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ibrahim Adjie Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodman Tarigan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puter Primary Health Center</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eddy Fadlyana</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

